Germany blocks deregulation of NGT breeds

At the EU Council (10-11 December), agriculture ministers did not reach the qualified majority required to adopt the <link https://data.consilium.europa.eu/doc/document/ST-16443-2023-INIT/en/pdf>adapted version of the EU Commission’s draft regulation</link> on new genomic […]

Cathera SA closes Series B round at €42m

Sorbonne University spin-out Carthera SA has closed its Series B financing round with an additional investment of €4.5m at €42m to launch clinical trials.<br /> &nbsp;<br />

UK publishes £2bn vision for engineering biology

On the occasion of SynbiTECH in London, British&nbsp;Science, Research and Innovation Minister, Andrew Griffith, unveiled a £2bn strategic 10-year plan to foster engineering biology.

Valnevas Lyme vaccine trial complets recruitment

Pfizer and Valneva announced the completion of enrolment in Phase 3 VALOR trial for Lyme borreliosis vaccine candidate VLA15. More then 9,000 participants were enrolled.

Unveiling prostate cancer's Achilles' heel

Researchers uncover a potential strategy to target and inhibit the androgen receptor in aggressive prostate cancer by exploiting protein droplets.

$30m for genetic medicine advancements

Eligo Bioscience secures $30m in series B funding, advancing its innovative gene-editing solutions targeting diseases linked to bacterial genes within the human microbiome.

Takeover in ADC space: Abbvie snags ImmunoGen

AbbVie buys ImmunoGen in US$10 billion deal, gains access to ADC for ovarian cancer. The ADC space gets hotter and hotter.

Repairing MS-caused damage with stem cells

British and Italian researchers have demostrated promising results in patients with progressive multiple sclerosis through stem cell transplantation into the brain.

Breakthrough in COPD treatment

French Sanofi SA’s second Phase III trial of duplimab demonstrated a 34% reduction in exacerbations and significant lung function improvements.